Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).

ABSTRACT:

Background

Simvastatin, 20mg, plus ezetimibe, 10mg, daily (simvastatin plus ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown.

Study design

Cost-effectiveness of simvastatin plus ezetimibe in SHARP, a randomized controlled trial.

Setting & population

9,270 patients with CKD randomly assigned to simvastatin plus ezetimibe versus placebo; participants in categories by 5-year cardiovascular risk (low, <10%; medium, 10%-<20%; or high, ≥20%) and CKD stage (3, 4, 5 not on dialysis, or on dialysis therapy).

Model, perspective, & timeline

Assessment during SHARP follow-up from the UK perspective; long-term projections.

SUBMITTER: Mihaylova B 

PROVIDER: S-EPMC4801501 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature